Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)

Seoulin Bioscience Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,949	14,602	8,999	14,973	8,498
Short-Term Investments	14,467	20,722	41,319	40,360	11,362
Trading Asset Securities	93.22	90.3	4,962	19,999	-
Cash & Short-Term Investments	23,510	35,414	55,280	75,332	19,860
Cash Growth	-33.62%	-35.94%	-26.62%	279.32%	-9.89%
Accounts Receivable	7,323	12,986	6,652	10,137	8,840
Other Receivables	528.24	1,291	630.36	196.33	68.33
Receivables	7,851	14,294	7,282	10,333	8,908
Inventory	26,245	21,785	17,307	13,933	11,748
Prepaid Expenses	13.63	53.74	51.32	32.59	20.85
Other Current Assets	2,222	1,408	7,366	5,352	924.78
Total Current Assets	59,841	72,955	87,287	104,983	41,462
Property, Plant & Equipment	16,628	18,914	16,491	14,937	14,541
Long-Term Investments	19,460	17,512	25,555	7,515	6,303
Goodwill	373.89	526.49	526.49	526.49	526.49
Other Intangible Assets	395.06	425.08	266.64	230.54	319.14
Long-Term Deferred Tax Assets	2,222	2,259	1,269	2,766	2,655
Long-Term Deferred Charges	107.82	156.08	210.96	558.01	1,715
Other Long-Term Assets	2,496	1,335	3,840	5,051	10,725
Total Assets	101,525	114,100	135,486	136,566	78,247
Accounts Payable	5,009	11,428	8,603	10,888	6,450
Accrued Expenses	390.22	387.97	373.05	329.11	278.89
Short-Term Debt	3,450	6,120	17,469	15,259	142.7
Current Portion of Long-Term Debt	-	-	62.5	256.25	229.9
Current Portion of Leases	156.68	271.44	69.22	34.65	3.07
Current Income Taxes Payable	-	700.11	730.13	4,561	749.54
Other Current Liabilities	4,628	9,122	19,058	28,112	5,679
Total Current Liabilities	13,634	28,030	46,365	59,440	13,533
Long-Term Debt	-	98.6	98.47	154.85	368.75
Long-Term Leases	73.29	224.29	86.11	32.85	9.92
Other Long-Term Liabilities	465.66	253.48	151.59	150	1,781
Total Liabilities	14,652	28,861	46,701	60,064	16,864
Common Stock	4,450	4,350	4,250	4,150	4,000
Additional Paid-In Capital	18,519	18,519	18,519	18,490	18,490
Retained Earnings	69,170	67,177	68,475	58,805	44,024
Treasury Stock	-4,496	-3,404	-3,261	-3,062	-2,981
Comprehensive Income & Other	-3,751	-3,581	-3,581	-3,523	-3,613
Total Common Equity	83,893	83,063	84,403	74,861	59,920
Minority Interest	2,980	2,177	4,382	1,642	1,463
Shareholders' Equity	86,872	85,239	88,785	76,502	61,383
Total Liabilities & Equity	101,525	114,100	135,486	136,566	78,247
Total Debt	3,680	6,714	17,785	15,738	754.35
Net Cash (Debt)	19,830	28,700	37,495	59,594	19,105
Net Cash Growth	-30.91%	-23.46%	-37.08%	211.92%	-12.29%
Net Cash Per Share	2274.97	3276.17	3447.13	6778.62	2171.72
Filing Date Shares Outstanding	8.76	8.56	8.57	8.57	8.47
Total Common Shares Outstanding	8.76	8.76	8.78	8.79	8.8
Working Capital	46,207	44,924	40,922	45,543	27,928
Book Value Per Share	9580.47	9477.06	9616.87	8517.25	6811.65
Tangible Book Value	83,124	82,111	83,610	74,104	59,074
Tangible Book Value Per Share	9492.66	9368.49	9526.50	8431.12	6715.52
Land	3,967	4,246	3,721	3,185	3,118
Buildings	11,263	12,539	11,192	10,642	10,563
Machinery	1,026	1,474	1,193	851.95	631.66
Construction In Progress	-	-	6	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.